Search Result
Results for "
RdRp inhibitor
" in MedChemExpress (MCE) Product Catalog:
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0879A
-
|
Suramin hexasodium salt
|
Phosphatase
Sirtuin
Reverse Transcriptase
Topoisomerase
SARS-CoV
Parasite
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
|
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM) . Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM) . Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .
|
-
-
- HY-14768
-
Favipiravir
Maximum Cited Publications
50 Publications Verification
T-705
|
DNA/RNA Synthesis
Influenza Virus
SARS-CoV
Bacterial
|
Infection
|
|
Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
|
-
-
- HY-10241
-
|
TMC435; TMC435350
|
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
|
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
-
- HY-146246
-
|
4'-FlU; 4'-Fluorouridine
|
RSV
SARS-CoV
HCV
|
Infection
|
|
EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses .
|
-
-
- HY-126303C
-
|
GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium
|
DNA/RNA Synthesis
SARS-CoV
RSV
HCV
Drug Metabolite
|
Infection
|
|
GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 μM, 5 μM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734) .
|
-
-
- HY-B1201
-
|
3,3',5-Triiodothyroacetic acid
|
Flavivirus
Thyroid Hormone Receptor
TNF Receptor
|
Endocrinology
|
|
Tiratricol is an orally available thyroid hormone analog that inhibits pituitary thyroid-stimulating hormone secretion. Tiratricol is an intracellular toxin neutralizer that inhibits LPS and lipid A cytotoxicity with IC50s of 20 μM and 32 μM, respectively. Tiratricol reduces TNF production in lipopolysaccharide-stimulated macrophages. Tiratricol also has antiviral activity and is an inhibitor of yellow fever virus (Flavivirus). It can bind to the RdRp domain of the viral NS5 protein to hinder YFV replication. .
|
-
-
- HY-18649
-
|
BCX4430 hydrochloride; Immucillin-A hydrochloride
|
DNA/RNA Synthesis
SARS-CoV
Filovirus
|
Infection
|
|
Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM .
|
-
-
- HY-18649A
-
|
BCX4430; Immucillin-A
|
DNA/RNA Synthesis
SARS-CoV
Filovirus
|
Infection
|
|
Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM .
|
-
-
- HY-B0879
-
|
|
Phosphatase
Sirtuin
Reverse Transcriptase
Topoisomerase
SARS-CoV
Parasite
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
|
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM) . Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM) . Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor .Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .
|
-
-
- HY-126303
-
|
GS-441524 triphosphate; Remdesivir metabolite
|
DNA/RNA Synthesis
SARS-CoV
RSV
HCV
Drug Metabolite
|
Infection
|
|
GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir .
|
-
-
- HY-131603
-
|
3TCTP
|
Reverse Transcriptase
HCV
HBV
SARS-CoV
Drug Derivative
|
Infection
|
|
Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .
|
-
-
- HY-128788
-
|
|
DNA/RNA Synthesis
SARS-CoV
Endogenous Metabolite
Flavivirus
Lactate Dehydrogenase
|
Infection
|
|
ddhCTP is an endogenously produced pyrimidine base analog with a Kd of 17.0 nM for LLDH and an IC50 of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP can be used in studies related to viral infections, COVID-19 and Zika virus infections.
|
-
-
- HY-75800
-
|
VX-222
|
DNA/RNA Synthesis
HCV
|
Infection
|
|
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .
|
-
-
- HY-149648
-
|
|
RSV
DNA/RNA Synthesis
|
Infection
|
|
JNJ-8003 is a potent and orally active non-nucleoside RSV polymerase inhibitor with an IC50 of 0.29 nM. JNJ-8003 targets the L protein polymerase complex of RSV (IC50 = 0.67 nM), and blocks the transcription and replication of the viral genome by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). JNJ-8003 displays subnanomolar activity in vitro as well as prominent efficacy in mice and a neonatal lamb models. JNJ-8003 can be used for the study of respiratory syncytial virus (RSV) .
|
-
-
- HY-10444
-
R-1479
3 Publications Verification
4'-Azidocytidine
|
HCV
DNA/RNA Synthesis
|
Infection
|
|
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
-
- HY-10443
-
|
Ro 4588161; R1626
|
HCV
DNA/RNA Synthesis
|
Infection
|
|
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
-
- HY-122587
-
|
|
DNA/RNA Synthesis
RSV
|
Infection
|
|
AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV) .
|
-
-
- HY-100749
-
-
-
- HY-134665
-
-
-
- HY-150234
-
-
-
- HY-10118
-
|
|
HCV
DNA/RNA Synthesis
|
Infection
|
|
Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .
|
-
-
- HY-155488
-
|
ATV014
|
SARS-CoV
|
Infection
|
|
SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of
coronavirus disease 2019 (COVID-19) .
|
-
-
- HY-13247
-
|
ANA598
|
DNA/RNA Synthesis
HCV
SARS-CoV
|
Infection
|
|
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition .
|
-
-
- HY-134909
-
|
|
DNA/RNA Synthesis
|
Infection
|
|
AS-136A is an orally active non-nucleoside inhibitor of the measles virus RNA-dependent RNA polymerase (RdRp) with an IC50 of 2 µM for measles virus .
|
-
-
- HY-139442
-
|
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
|
RdRP-IN-2 is a RNA dependent RNA polymerase (RdRp) inhibitor. RdRP-IN-2 significantly inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 μM.RdRP-IN-2 also inhibits Feline coronavirus (FIPV) replication .
|
-
-
- HY-151526
-
|
|
Virus Protease
Flavivirus
|
Infection
|
|
LabMol-301 inhibits both NS5 RdRp and NS2B-NS3pro activity (IC50: 0.8 and 7.4 μM, respectively). LabMol-301 has a cytoprotective effect and prevents Zika virus (ZIKV)-induced cell death .
|
-
-
- HY-161356
-
|
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
|
BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC50 for SARS-CoV-2 and HCoV-229E are 0.62 μM and 0.14 μM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077) .
|
-
-
- HY-143494
-
|
|
RSV
Influenza Virus
|
Infection
|
|
RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage .
|
-
-
- HY-162793
-
|
|
DNA/RNA Synthesis
Influenza Virus
|
Infection
|
|
RdRP-IN-8 (compound 45) is an anti-influenza virus compound. RdRP-IN-8 inhibits viral RNA-dependent RNA polymerase (RdRP) activity by disrupting heterodimerization of PA and PB1 subunits (EC50=0.13 μM) .
|
-
-
- HY-131976
-
|
|
Flavivirus
|
Infection
|
|
BVDV-IN-1 is a non-nucleoside inhibitor (NNI) of bovine viral diarrhea virus (BVDV), with an EC50 of 1.8 μM. BVDV-IN-1 directly binds to a hydrophobic pocket of the BVDV RdRp. BVDV-IN-1 has antiviral activity against BVDV resistant to NNI thiosemicarbazone (TSC) .
|
-
-
- HY-170799
-
|
|
DNA/RNA Synthesis
SARS-CoV
Arenavirus
|
Infection
|
|
HNC-1664 is the orally active inhibitor for RNA-dependent RNA polymerase (RdRP). HNC-1664 exhibits broad-spectrum antiviral activity against coronavirus (SARS-CoV-2 wildtype and its mutants XBB.1.18, HK.3.1, BF.7.14, BA.1HCoV-229E, HCoV-OC43) and arenavirus. HNC-1664 exhibits anti-infectious activity in SARS-CoV-2 Delta infected mouse models .
|
-
-
- HY-124590
-
|
|
HCV
|
Infection
|
|
IDX-17119 is a non-nucleoside HCV NS5B RdRp inhibitor with an IC50 of 0.4 nM .
|
-
-
- HY-131603B
-
|
3TCTP TEA
|
Reverse Transcriptase
HCV
HBV
SARS-CoV
Drug Derivative
|
Infection
|
|
Lamivudine triphosphate (3TCTP) TEA is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate TEA inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate TEA is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate TEA can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .
|
-
-
- HY-14768A
-
|
T-705 sodium
|
DNA/RNA Synthesis
Influenza Virus
SARS-CoV
Bacterial
|
Infection
|
|
Favipiravir (T-705) sodium is an inhibitor of viral RNA polymerase (RNA polymerase), which is converted into its active form Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the activity of influenza virus RNA-dependent RNA polymerase (RdRP) with an IC50 of 341 nM .
|
-
-
- HY-14768R
-
|
T-705 (Standard)
|
Reference Standards
DNA/RNA Synthesis
Influenza Virus
SARS-CoV
Bacterial
|
Infection
|
|
Favipiravir (Standard) is the analytical standard of Favipiravir. This product is intended for research and analytical applications. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
|
-
-
- HY-14768S
-
|
T-705-13C15N
|
Isotope-Labeled Compounds
Bacterial
DNA/RNA Synthesis
SARS-CoV
Influenza Virus
|
Infection
|
|
Favipiravir- 13C 15N (T-705- 13C 15N) is 13C and 15N labeled Favipiravir. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
|
-
-
- HY-10241A
-
|
TMC435 sodium; TMC435350 sodium
|
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
|
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
-
- HY-B1201R
-
|
3,3',5-Triiodothyroacetic acid (Standard)
|
Flavivirus
Thyroid Hormone Receptor
Reference Standards
TNF Receptor
|
Endocrinology
|
|
Tiratricol (Standard) is the analytical standard of Tiratricol. This product is intended for research and analytical applications. Tiratricol is an orally available thyroid hormone analog that inhibits pituitary thyroid-stimulating hormone secretion. Tiratricol is an intracellular toxin neutralizer that inhibits LPS and lipid A cytotoxicity with IC50s of 20 μM and 32 μM, respectively. Tiratricol reduces TNF production in lipopolysaccharide-stimulated macrophages. Tiratricol also has antiviral activity and is an inhibitor of yellow fever virus (Flavivirus). It can bind to the RdRp domain of the viral NS5 protein to hinder YFV replication. .
|
-
-
- HY-10241S
-
|
TMC435-13C,d3; TMC435350-13C,d3
|
Isotope-Labeled Compounds
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
|
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
-
- HY-114571
-
|
cis-VX-222
|
DNA/RNA Synthesis
HCV
|
Infection
|
|
cis-Lomibuvir (cis-VX-222) is the cis-isomer of Lomibuvir. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis . cis-Lomibuvir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-174373
-
|
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
|
SARS-CoV-2-IN-113 (Compound 24) is a sulfonohydrazide derivative against SARS-CoV-2 infection with an IC50 of 8.320 μM. SARS-CoV-2-IN-113 exerts potent antiviral effects by inhibiting the entry and replication of SARS-CoV-2, and downregulating the expression of genes and proteins such as Spike, ACE-2, and RdRp. SARS-CoV-2-IN-113 has high selectivity and low cytotoxicity, and can be used in the research of SARS-CoV-2 .
|
-
-
- HY-B0879AR
-
|
Suramin hexasodium salt (Standard)
|
Reference Standards
Phosphatase
Sirtuin
Reverse Transcriptase
Topoisomerase
SARS-CoV
Parasite
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
|
Suramin (sodium salt) (Standard) is the analytical standard of Suramin (sodium salt). This product is intended for research and analytical applications. Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM) . Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM) . Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .
|
-
-
- HY-154990
-
|
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
|
RdRP-IN-7 is a RNA-dependent RNA polymerase (RdRp) inhibitor that shows the inhibition of SARS-CoV-2 infection with an IC50 of 8.2 μM, an IC90 of 14.1 μM and an CC90 of 79.1 μM. RdRP-IN-7 can be used for antiviral research .
|
-
-
- HY-16750
-
|
GS-9669
|
DNA/RNA Synthesis
HCV
|
Infection
|
|
Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC50 = 2.9 nM, GT1b EC50 = 6 nM) .
|
-
-
- HY-152239
-
-
-
- HY-152239B
-
|
|
DNA/RNA Synthesis
Influenza Virus
|
Infection
|
|
trans-RdRP-IN-5 (compound 18) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. trans-RdRP-IN-5 can be used in research of influenza virus .
|
-
-
- HY-152239A
-
|
|
DNA/RNA Synthesis
Influenza Virus
|
Infection
|
|
cis-RdRP-IN-5 (compound 19) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. cis-RdRP-IN-5 can be used in research of influenza virus .
|
-
-
- HY-154989
-
|
|
DNA/RNA Synthesis
|
Infection
Cancer
|
|
RdRP-IN-6 (compound 27) inhibits RNA dependent-RNA polymerase (RdRp) with an IC90 value of 14.1 μM. RdRP-IN-6 can be used for research on antiviral and anticancer .
|
-
-
- HY-115730
-
-
-
- HY-173134
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2 RdRp-IN-1 (Compound PAP-2) is a potent SARS-CoV-2 RdRp inhibitor, with an EC50 of 1.11 μM. SARS-CoV-2 RdRp-IN-1 can bind directly to SARS-CoV-2 RdRp, fully resistance to the exoribonuclease (ExoN) and exhibit broad spectrum anti-CoV activities .
|
-
- HY-144668
-
|
|
DNA/RNA Synthesis
Influenza Virus
|
Infection
|
|
RdRP-IN-4 (compound 11q), an aryl benzoyl hydrazide analog, is an orally active influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor by interacting with the PB1 subunit. RdRP-IN-4 exhibits potent inhibitory activity against the avian H5N1 flu strain with an EC50 of 18 nM in MDCK cells. RdRP-IN-4 displays excellent potency against the the H1N1 (A/PR/8/34) Flu A strain and Flu B strain (B/Lee/1940) with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 significantly inhibits the expression level of viral nucleoprotein (NP) in a dose-dependent manner. RdRP-IN-4 exhibits significant antiviral activity in infected mice .
|
-
- HY-170649
-
|
|
SARS-CoV
|
Infection
|
|
RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC50 value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structural protein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) .
|
-
- HY-18223
-
|
|
Dengue Virus
|
Infection
|
|
NITD-203 is a RdRp domain inhibitor. NITD 203 induces inhibition of the four DENV serotypes, as well as of YFV and WNV .
|
-
- HY-156440
-
|
|
Influenza Virus
|
Infection
|
|
7-51A is a potent PB2 inhibitor with a KD value of 1.64 nM as determined by ITC. PB2 is an essential subunit of influenza RNA-dependent RNA polymerase (RdRP).
|
-
- HY-160704
-
-
- HY-162924
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-IN-6 (Compound 17) is an inhibitor of SARS-CoV-1 and SARS-CoV-2 RdRp, with an IC50 value of 7.8 μM against SARS-CoV-2 RdRp. SARS-CoV-IN-6 reduces cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs), and inhibits SARS-CoV N protein expression, with EC50 values of 0.12 µM for SARS-CoV-1 replicon-based SRIPs and 1.47 µM for SARS-CoV-2 replicon-based SRIPs .
|
-
- HY-134991
-
-
- HY-155053
-
|
|
Flavivirus
DNA/RNA Synthesis
|
Inflammation/Immunology
|
|
ZIKV-IN-6 (compound 22) is an inhibitor of Zika virus (ZIKV), with low cytotoxicity (CC50>50 μM). ZIKV-IN-6 binds to ZIKV RdRp directly and inhibits viral RNA synthesis by ZIKV NS5. ZIKV-IN-6 suppresses the excessive inflammatory response and pyroptosis .
|
-
- HY-134991A
-
-
- HY-159890
-
|
|
SARS-CoV
|
Infection
|
|
MTI013 is a selective SARS-CoV-2 nsp14 Mtase inhibitor (IC50: 2.98 μM) and an antiviral agent (IC50: 10.33 μM in HCoV-229E-infected Huh7 cells). MTI013 also shows a synergistic antiviral effect with the RdRp inhibitor SHEN26 (HY-155488) .
|
-
- HY-W769714
-
|
T-705-13C3
|
Isotope-Labeled Compounds
DNA/RNA Synthesis
Influenza Virus
|
Infection
|
|
Favipiravir- 13C3 is the 13C labeled isotope of Favipiravir (HY-14768). Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
|
-
- HY-115929
-
|
|
DNA/RNA Synthesis
|
Infection
|
|
DENV-IN-4 is a potent DENV inhibitor (DENV EC50=4.79 μM, Vero CC50>100 μM, SI>20.9). DENV-IN-4 can inhibit the expression level of DENV2 with concentration-dependence and reduce RNA-dependent RNA polymerase (RdRp) enzymatic activity. DENV-IN-4 has antiviral effect .
|
-
- HY-174370
-
|
|
SARS-CoV
|
Infection
|
|
MePT-S-N-Pme is an inhibitor of SARS-CoV-2 RdRp activity. MePT-S-N-Pme demonstrates a significant reduced reporter activity with an IC50 of 7 μM in HEK 293 cells. MePT-S-N-Pme has a slight inhibitory effect on nucleotidyltransferase activity. MePT-S-N-Pme significantly inhibits SARS-CoV-2 replication in vitro .
|
-
- HY-157022
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivatives, has anti-SARS-CoV-2 activity (EC50: 64.8 μM in VeroE6/TMPRSS2 cells). SARS-CoV-2-IN-67 inhibits SARS-CoV-2 RdRp activity .
|
-
- HY-168510
-
|
|
Influenza Virus
|
Infection
|
|
ATV03 is an anti-influenza virus agent with excellent anti-influenza A and B virus activity. ATV03 inhibits anti-influenza A (H3N2) and anti-influenza B with EC50 values of 0.78 nM and 2.02 nM, respectively. ATV03 exerts anti-influenza activity by inhibiting polymerase acidic protein (PA) and RNA-dependent RNA polymerase (RdRp), as well as disrupting nuclear protein .
|
-
- HY-168473
-
|
|
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
|
13-TP is an inhibitor of SARS-CoV-2. 13-TP effectively inhibits the SARS-CoV-2 central replication transcription complex (C-RTC, nsp12-nsp7-nsp82) catalyzed in vitro RNA synthesis. 13-TP completely inhibits the RdRp polymerization activity. 13-TP blocks the full extension of some of the primer RNA .
|
-
- HY-75800R
-
|
VX-222 (Standard)
|
DNA/RNA Synthesis
HCV
Reference Standards
|
Infection
|
|
Lomibuvir (Standard) is the analytical standard of Lomibuvir. This product is intended for research and analytical applications. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .
|
-
- HY-162719
-
|
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
|
RH12 is a dual inhibitor for SARS-CoV-2 related RNA-dependent RNA polymerase (RdRp, IC50 is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC50 is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC50 of 17.5 nM .
|
-
- HY-151254
-
|
|
Cytochrome P450
Influenza Virus
DNA/RNA Synthesis
|
Infection
|
|
CYP2C19-IN-1 (compound 20d) is a potent CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) with a Ki value of 6.16 µM. CYP2C19-IN-1 can be used in study of anti-ZIKV .
|
-
- HY-146957
-
|
|
Virus Protease
Flavivirus
|
Cancer
|
|
ZIKV-IN-1 is a potent zika virus inhibitor with an EC50 of 2.8 μM and EC90 of 6.8 μM. ZIKV-IN-1 shows anti-ZIKV activity with low cytotoxicity. ZIKV-IN-1 shows a strong affinity to ZIKV RdRp domain . ZIKV-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-10443A
-
|
Ro 4588161 hydrochloride; R1626 hydrochloride
|
HCV
DNA/RNA Synthesis
|
Infection
|
|
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-174439
-
|
|
SARS-CoV
Virus Protease
Drug Metabolite
|
Infection
|
|
Nsp12-IN-2 (Compound 8), the triphosphate metabolite of 4'-thiouridine (HY-W113081), is a SARS-CoV-2 Nsp12 inhibitor. Nsp12-IN-2 inhibits the RNA-dependent RNA polymerase (RdRp) activity of the SARS-CoV-2 Nsp12-Nsp7-Nsp8 complex, terminates RNA synthesis and also blocks the RNAylation and NMPylation of Nsp9. Nsp12-IN-2 is promising for research of infections caused by SARS-CoV-2, other coronaviruses, and other RNA viruses .
|
-
- HY-158028
-
|
|
Influenza Virus
|
Infection
|
|
PAN endonuclease-IN-2 (compound T-31) is a PAN endonuclease inhibitor (IC50: 0.15 μM) and antiviral agent with broad-spectrum anti- Influenza activity. PAN is the N-terminal PA subunit of the polymerase-RNA complex and the dependent endonuclease (CEN) active site. PAN initiates RNA replication by promoting cleavage of the RNA strand and allowing the polymerase to begin synthesizing new RNA molecules. PAN endonuclease-IN-2 targets both the influenza HA and RdRp complexes, thereby interfering with viral entry into host cells and viral replication .
|
-
- HY-10443R
-
|
Ro 4588161 (Standard); R1626 (Standard)
|
Reference Standards
HCV
DNA/RNA Synthesis
|
Infection
|
|
Balapiravir (Standard) is the analytical standard of Balapiravir. This product is intended for research and analytical applications. Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-180673
-
|
|
SARS-CoV
Virus Protease
|
Infection
|
|
Mpro/RdRp-IN-1 (Compound 1) is a dual-target inhibitor against SARS-CoV-2, targeting RdRp (EC50 = 25.45) and Mpro (IC50 = 125.4 μM). Mpro/RdRp-IN-1 exhibits EC₅₀ for HCoV-OC43 of 4.79 μM, and the selectivity index (SI) is 10.89. Mpro/RdRp-IN-1 can be used for studying SARS-CoV-2 and HCoV-OC43 infections .
|
-
- HY-182761
-
|
|
DNA/RNA Synthesis
Cytochrome P450
Flavivirus
Influenza Virus
|
Infection
|
|
Antiviral agent 81 is an orally bioavailable N-acylated remdesivir derivative and RdRp inhibitor with 45.3% oral bioavailability (based on active metabolite GS-441524 exposure), plasma half-life >8 h, and reduced CYP3A4 inhibition. Antiviral agent 81 exhibits activity against Coronaviridae, Flaviviridae, and Pneumoviridae, and shows no activity against Orthomyxoviridae, Herpesviridae, and Alphaviridae. Antiviral agent 81 can be used for the research of viral infections .
|
-
- HY-181778
-
|
|
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
|
RdRP-IN-10 is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor with an IC50 value of 5.78 μM. RdRP-IN-10 forms covalent binds with SARS-CoV-2 nsp8 Cys114, disrupts nsp8-nsp12 stabilizing interactions. RdRP-IN-10 inhibits SARS-CoV-2 RdRp-mediated RNA polymerization without interfering with RNA-RdRp complex binding. RdRP-IN-10 exerts antiviral effects in cellular models. RdRP-IN-10 can be used for the research of SARS-CoV-2 infection .
|
-
- HY-100749R
-
|
|
Flavivirus
Dengue Virus
SARS-CoV
Reference Standards
|
Infection
|
|
HeE1-2Tyr (Standard) is the analytical standard of HeE1-2Tyr (HY-100749). This product is intended for research and analytical applications. HeE1-2Tyr, a pyridobenzothiazole compound, is a flavivirus RNA dependent RNA polymerases (RdRp) inhibitor. HeE1-2Tyr significantly inhibits West Nile, Dengue and SARS-CoV-2 RdRps (IC50 of 27.6 μM) activity in vitro .
|
-
- HY-128788A
-
|
|
DNA/RNA Synthesis
SARS-CoV
Endogenous Metabolite
Flavivirus
Lactate Dehydrogenase
|
Infection
|
|
ddhCTP trisodium solution (100 mM) is an endogenously produced pyrimidine base analog with a Kd of 17.0 nM for LLDH and an IC50 of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP trisodium reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP trisodium terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP trisodium can be used in studies related to viral infections, COVID-19 and Zika virus infections .
|
-
- HY-186075
-
|
|
Flavivirus
Orthopoxvirus
SARS-CoV
CHIKV
Enterovirus
|
Infection
|
|
PS1097 is a broad-spectrum antiviral inhibitor with a BVDV RdRp IC50 of 0.64 μM. PS1097 selectively reduces RTN3 protein levels, causes partial RTN3 mRNA reduction, and leaves other endoplasmic reticulum-resident proteins unaffected. PS1097 inhibits replication of Zika virus and multiple viruses that use the endoplasmic reticulum as a replication hub. PS1097 inhibits BVDV RdRp enzymatic activity and exerts activity against Bovine Viral Diarrhea Virus. PS1097 can be used for the research of zika virus infection, usutu virus infection, west nile virus infection, COVID-19, coxsackie b virus 5 infection, chikungunya virus infection, vaccinia virus infection .
|
-
- HY-181987
-
|
|
Dengue Virus
DNA/RNA Synthesis
|
Infection
|
|
PSCdb01560 is a Dengue virus NS5 RNA-dependent RNA polymerase (RdRp) inhibitor. PSCdb01560 binds stably to the conserved allosteric N-pocket of the polymerase, maintains persistent interactions with key residues Arg729 and Arg737, and induces polymerase structure stabilization. PSCdb01560 can be used for the research of dengue virus infection .
|
-
- HY-180269
-
|
|
Influenza Virus
DNA/RNA Synthesis
|
Infection
|
|
Anti-Influenza agent 10 (Compound 41) is an influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor. Anti-Influenza agent 10 exhibits potent antiviral activity against A/PR/8/34(H1N1) with an IC50 of 0.29μM and a KD of 4.11 μM. Anti-Influenza agent 10 can inhibit the assembly of the viral RdRp complex by disrupting the protein interaction between PA and PB1 subunits, thereby blocking the transcription and replication of the viral genome. Anti-Influenza agent 10 shows significant broad-spectrum effects on multiple influenza virus strains, such as H3N2, H3N8 and H9N2 with IC50 values of 3.96, 1.91 and 1.45 μM. Anti-Influenza agent 10 can be used for the research of influenza A Virus Infection .
|
-
- HY-181176
-
|
|
NADPH Oxidase
SARS-CoV
Virus Protease
|
Infection
Inflammation/Immunology
|
|
DEMAMP is an antioxidant. DEMAMP exhibits scavenging effects on DPPH and H2O2 free radicals, with IC50 values of 0.60 and 0.48 mg/mL, respectively. Molecular docking simulations show that DEMAMP potently inhibits NADPH oxidase and the Mpro and RdRp proteins of SARS-CoV-2, and ADMET analysis confirms that it has favorable oral bioavailability. DEMAMP can be used in studies related to COVID-19 .
|
-
- HY-183746
-
|
|
P-glycoprotein
SARS-CoV
Virus Protease
|
Infection
|
|
Catechin-5-O-gallate is a bioactive substance. Catechin-5-O-gallate can be isolated from bioactive Himalayan plants. Catechin-5-O-gallate is predicted to be a P-glycoprotein inhibitor, and binds to SARS-CoV-2 3CLpro, PLpro and RdRp. Catechin-5-O-gallate can be used in studies related to COVID-19 .
|
-
- HY-10241R
-
|
TMC435 (Standard); TMC435350 (Standard)
|
Reference Standards
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
|
Simeprevir (Standard) is the analytical standard of Simeprevir (HY-10241). This product is intended for research and analytical applications. Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
- HY-10444R
-
|
4'-Azidocytidine (Standard)
|
Reference Standards
HCV
DNA/RNA Synthesis
|
Infection
|
|
R-1479 (Standard) is the analytical standard of R-1479 (HY-10444). This product is intended for research and analytical applications. R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-14768S
-
|
|
|
Favipiravir- 13C 15N (T-705- 13C 15N) is 13C and 15N labeled Favipiravir. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
|
-
-
- HY-10241S
-
|
|
|
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
-
- HY-W769714
-
|
|
|
Favipiravir- 13C3 is the 13C labeled isotope of Favipiravir (HY-14768). Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-10444
-
R-1479
3 Publications Verification
4'-Azidocytidine
|
|
Azide
|
|
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-10443
-
|
Ro 4588161; R1626
|
|
Azide
|
|
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-18223
-
|
|
|
Alkynes
|
|
NITD-203 is a RdRp domain inhibitor. NITD 203 induces inhibition of the four DENV serotypes, as well as of YFV and WNV .
|
-
- HY-10443A
-
|
Ro 4588161 hydrochloride; R1626 hydrochloride
|
|
Azide
|
|
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-10444
-
R-1479
3 Publications Verification
4'-Azidocytidine
|
|
Nucleoside Analogs
Cytidine
|
|
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: